JP2019528279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528279A5 JP2019528279A5 JP2019508942A JP2019508942A JP2019528279A5 JP 2019528279 A5 JP2019528279 A5 JP 2019528279A5 JP 2019508942 A JP2019508942 A JP 2019508942A JP 2019508942 A JP2019508942 A JP 2019508942A JP 2019528279 A5 JP2019528279 A5 JP 2019528279A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- cycloalkyl
- group
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CMXLWMLABMJODV-UHFFFAOYSA-N Cc(cc1C(F)(F)F)ccc1Cl Chemical compound Cc(cc1C(F)(F)F)ccc1Cl CMXLWMLABMJODV-UHFFFAOYSA-N 0.000 description 2
- OLECYYBXISHMFS-YGKWUCAESA-N CC(C)/C(/C=C(\C)/C(F)(F)F)=C(/C#C)\F Chemical compound CC(C)/C(/C=C(\C)/C(F)(F)F)=C(/C#C)\F OLECYYBXISHMFS-YGKWUCAESA-N 0.000 description 1
- RWIKZAWYMHSEOC-UHFFFAOYSA-N CC(C)c(cc1)cc(C(F)(F)F)c1F Chemical compound CC(C)c(cc1)cc(C(F)(F)F)c1F RWIKZAWYMHSEOC-UHFFFAOYSA-N 0.000 description 1
- BYPOENRTPJTXAT-UHFFFAOYSA-N CC(C)c1cccc(C(F)(F)F)c1 Chemical compound CC(C)c1cccc(C(F)(F)F)c1 BYPOENRTPJTXAT-UHFFFAOYSA-N 0.000 description 1
- HNKGOFAGRUMTEG-UHFFFAOYSA-N CCc1ccc(C(F)(F)F)c(Cl)c1 Chemical compound CCc1ccc(C(F)(F)F)c(Cl)c1 HNKGOFAGRUMTEG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376138P | 2016-08-17 | 2016-08-17 | |
| US62/376,138 | 2016-08-17 | ||
| PCT/US2017/047383 WO2018035346A1 (en) | 2016-08-17 | 2017-08-17 | Kinase inhibitor compounds, compositions, and methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528279A JP2019528279A (ja) | 2019-10-10 |
| JP2019528279A5 true JP2019528279A5 (OSRAM) | 2020-09-17 |
Family
ID=61197083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508942A Pending JP2019528279A (ja) | 2016-08-17 | 2017-08-17 | キナーゼ阻害物質化合物、組成物、及びがんの治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10519113B2 (OSRAM) |
| EP (1) | EP3500257B1 (OSRAM) |
| JP (1) | JP2019528279A (OSRAM) |
| CN (1) | CN110072526A (OSRAM) |
| CA (1) | CA3034332A1 (OSRAM) |
| WO (1) | WO2018035346A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108440404A (zh) * | 2018-05-08 | 2018-08-24 | 西安凯伦生物科技有限公司 | 具有多重激酶抑制作用的抗肿瘤药物及其制备方法和应用 |
| CN111362871B (zh) * | 2018-12-25 | 2022-05-17 | 北京福元医药股份有限公司 | 取代的吡啶-2-甲酰胺类化合物及其用途 |
| EP4115907A4 (en) | 2020-02-27 | 2024-07-03 | National University Corporation Hokkaido University | METHODS OF SCREENING ANTI-CANCER AGENTS AND COMBINATION MEDICINAL AGENTS OF KINASE INHIBITORS FOR THE TREATMENT OF PANCREAS CANCER |
| CN113402456B (zh) * | 2020-03-16 | 2023-03-03 | 深圳大学 | 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用 |
| CA3182673A1 (en) * | 2020-05-08 | 2021-11-11 | Georgiamune Llc | Akt3 modulators |
| WO2022094477A1 (en) * | 2020-11-02 | 2022-05-05 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancers having dysregulated wnt signaling pathways |
| KR102710925B1 (ko) * | 2021-06-01 | 2024-09-27 | 부산대학교 산학협력단 | 신규 스퀘어아마이드 유도체 및 이의 용도 |
| WO2025083280A1 (en) * | 2023-10-19 | 2025-04-24 | Universitat De Barcelona | Sorafenib analogs for use in the treatment of cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4437270B2 (ja) * | 1997-12-22 | 2010-03-24 | バイエル コーポレイション | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 |
| US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CA2475818C (en) * | 2002-02-11 | 2011-07-19 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
| WO2004014870A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| JP5229853B2 (ja) * | 2003-02-28 | 2013-07-03 | ニッポネックス インコーポレイテッド | 癌その他の疾患の治療に有用な新規な二環尿素誘導体 |
| ATE489379T1 (de) * | 2003-02-28 | 2010-12-15 | Bayer Healthcare Llc | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen |
| DE602004011340T2 (de) * | 2003-05-20 | 2008-11-06 | Bayer Healthcare Llc | Diaryl-harnstoffe mit kinasehemmender wirkung |
| CA2531485C (en) * | 2003-07-07 | 2013-03-26 | Merck Patent Gmbh | Malonamide derivatives |
| NZ544920A (en) * | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| US20060078617A1 (en) * | 2004-08-27 | 2006-04-13 | Fritz Schueckler | Pharmaceutical compositions for the treatment of cancer |
| US8580798B2 (en) * | 2005-12-21 | 2013-11-12 | Bayer Intellectual Property Gmbh | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
| US20100004253A1 (en) * | 2006-09-19 | 2010-01-07 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| CN101260106A (zh) * | 2007-03-06 | 2008-09-10 | 中国药科大学 | Raf激酶抑制剂及其制备方法和用途 |
| US20090012091A1 (en) * | 2007-07-02 | 2009-01-08 | Kinagen, Inc. | Oximide derivatives and their therapeutical application |
| CN101723890B (zh) * | 2008-10-10 | 2011-11-23 | 中国科学院成都生物研究所 | 芳基硫脲及其制备方法和用途 |
| JP2011063516A (ja) * | 2009-09-15 | 2011-03-31 | Daiichi Sankyo Co Ltd | アミド誘導体 |
| WO2011046991A2 (en) * | 2009-10-15 | 2011-04-21 | Gilead Connecticut, Inc. | Certain substituted ureas as modulators of kinase activity |
| CA2826277A1 (en) * | 2011-02-14 | 2012-08-23 | The Regents Of The University Of California | Sorafenib derivatives as seh inhibitors |
| KR101661825B1 (ko) * | 2011-08-03 | 2016-09-30 | 내셔널 타이완 유니버시티 | Ｓｒｃ 상동성-2 함유 단백질 티로신 포스파타제-1의 작용물질 및 그를 사용한 치료방법 |
| US9090617B1 (en) * | 2011-08-03 | 2015-07-28 | National Taiwan University | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
| CN103508961B (zh) * | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| US10449182B2 (en) * | 2012-07-06 | 2019-10-22 | The Regents Of The University Of California | Sorafenib derivatives as p21 inhibitors |
| WO2015051149A1 (en) * | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Sorafenib analogs and uses thereof |
-
2017
- 2017-08-17 EP EP17842133.5A patent/EP3500257B1/en active Active
- 2017-08-17 CN CN201780062024.1A patent/CN110072526A/zh active Pending
- 2017-08-17 WO PCT/US2017/047383 patent/WO2018035346A1/en not_active Ceased
- 2017-08-17 JP JP2019508942A patent/JP2019528279A/ja active Pending
- 2017-08-17 CA CA3034332A patent/CA3034332A1/en active Pending
- 2017-08-17 US US16/325,218 patent/US10519113B2/en active Active
-
2019
- 2019-11-14 US US16/684,159 patent/US11066370B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528279A5 (OSRAM) | ||
| JP2021169499A5 (OSRAM) | ||
| JP2020169171A5 (OSRAM) | ||
| JP2017504642A5 (OSRAM) | ||
| JP2011509309A5 (OSRAM) | ||
| JP2006501295A5 (OSRAM) | ||
| JP2009506119A5 (OSRAM) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2013209405A5 (OSRAM) | ||
| JP2020522567A5 (OSRAM) | ||
| JP2018135343A5 (OSRAM) | ||
| JP2003520195A5 (OSRAM) | ||
| JP2020502047A5 (OSRAM) | ||
| JP2017538689A5 (OSRAM) | ||
| JP2013533253A5 (OSRAM) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2020532545A5 (OSRAM) | ||
| JP2021046404A5 (OSRAM) | ||
| JP2016531126A5 (OSRAM) | ||
| JPWO2021069705A5 (OSRAM) | ||
| JP2018514568A5 (OSRAM) | ||
| JP2010505865A5 (OSRAM) | ||
| JP2017522304A5 (OSRAM) | ||
| JPWO2019165358A5 (OSRAM) | ||
| RU2018133288A (ru) | Комбинированные терапии для лечения спинальной мышечной атрофии |